K
Kathleen T. Montone
Researcher at University of Pennsylvania
Publications - 207
Citations - 9227
Kathleen T. Montone is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 46, co-authored 191 publications receiving 7889 citations. Previous affiliations of Kathleen T. Montone include University of Hong Kong & Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers
Xiaohui Yan,Xiaohui Yan,Zhongyi Hu,Yi Feng,Xiaowen Hu,Jiao Yuan,Sihai Dave Zhao,Youyou Zhang,Lu Yang,Lu Yang,Weiwei Shan,Weiwei Shan,Qun He,Lingling Fan,Lingling Fan,Lana E. Kandalaft,Lana E. Kandalaft,Janos L. Tanyi,Chunsheng Li,Chao-Xing Yuan,Dongmei Zhang,Dongmei Zhang,Huiqing Yuan,Keqin Hua,Yiling Lu,Dionyssios Katsaros,Qihong Huang,Kathleen T. Montone,Yi Fan,George Coukos,Jeff Boyd,Anil K. Sood,Timothy R. Rebbeck,Gordon B. Mills,Chi V. Dang,Lin Zhang +35 more
TL;DR: A comprehensive analysis of lncRNA alterations at transcriptional, genomic, and epigenetic levels in 5,037 human tumor specimens across 13 cancer types from The Cancer Genome Atlas suggests that the expression and dysregulation of lNCRNAs are highly cancer type specific compared with protein-coding genes.
Journal ArticleDOI
Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers
Shan Deng,Shan Deng,Xiaojun Yang,Xiaojun Yang,Heini Lassus,Shun-Zhi Liang,Sippy Kaur,Qunrui Ye,Chunsheng Li,Li-Ping Wang,Katherine F. Roby,Sandra Orsulic,Denise C. Connolly,Youcheng Zhang,Kathleen T. Montone,Ralf Bützow,George Coukos,Lin Zhang +17 more
TL;DR: It is found that high AL DH1 expression is significantly associated with poor clinical outcomes in serous ovarian cancer patients and high ALDHbr tumor cells exhibit cancer stem cell properties and are resistant to chemotherapy.
Journal ArticleDOI
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
Denarda Dangaj,Marine Bruand,Alizée J. Grimm,Catherine Ronet,David Barras,Priyanka Duttagupta,Evripidis Lanitis,Jaikumar Duraiswamy,Janos L. Tanyi,Fabian Benencia,Jose R. Conejo-Garcia,Hena R. Ramay,Kathleen T. Montone,Daniel J. Powell,Phyllis A. Gimotty,Andrea Facciabene,Donald G. Jackson,Jeffrey S. Weber,Scott J. Rodig,Stephen Hodi,Lana E. Kandalaft,Melita Irving,Lin Zhang,Periklis G. Foukas,Sylvie Rusakiewicz,Mauro Delorenzi,Mauro Delorenzi,George Coukos +27 more
TL;DR: The cooperation between tumor-derived CCL5 and IFN-γ-inducible CXCR3 ligands secreted by myeloid cells is key for orchestrating T cell infiltration in immunoreactive and immunoresponsive tumors.
Journal ArticleDOI
A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer
Xiaowen Hu,Yi Feng,Dongmei Zhang,Dongmei Zhang,Sihai Dave Zhao,Zhongyi Hu,Joel Greshock,Youyou Zhang,Lu Yang,Lu Yang,Xiaomin Zhong,Xiaomin Zhong,Li-Ping Wang,Stephanie Jean,Chunsheng Li,Qihong Huang,Dionyssios Katsaros,Kathleen T. Montone,Janos L. Tanyi,Yiling Lu,Jeff Boyd,Katherine L. Nathanson,Hongzhe Li,Gordon B. Mills,Lin Zhang +24 more
TL;DR: This work has identified an oncogene, focally amplified lncRNA on chromosome 1 (FAL1), whose copy number and expression are correlated with outcomes in ovarian cancer, and FAL1-specific siRNAs significantly inhibit tumor growth in vivo.
Journal ArticleDOI
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.
Donald E. Tsai,Christine Hardy,John E. Tomaszewski,Robert M. Kotloff,Kimberly M. Oltoff,Bradley G. Somer,Stephen J. Schuster,David L. Porter,Kathleen T. Montone,Edward A. Stadtmauer +9 more
TL;DR: Reduction in immunosuppression is an effective initial therapy for Posttransplant lymphoproliferative disorder and clinical prognostic factors may allow clinicians to identify which patients are likely to respond to reduction in immuno- suppression.